Five Prime Therapeutics (FPRX) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Five Prime Therapeutics Reports Third Quarter 2020 Results
November 3, 2020 4:05 PM ESTTop-Line Phase 2 FIGHT data on track to be announced in 2020 FPT155 advancing to year-end goal of informing next steps for the program Enrollment in the monotherapy exploratory cohort continues at the 560mg dose Enrollment in the dose escalation of FPT155 in combination with pembrolizumab has advanced to the second cohort in patients with non-small cell lung cancer Novel antibody targeting CCR8 moves into IND-enabling studies Year-end cash guidance raised to $100 to $105 million
SOUTH SAN FRANCISCO, Calif.--(BUSINESS... More
